Drug delivery systems in the treatment of African trypanosomiasis infections

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Expert Opinion on Drug Delivery

• Publication date

  2011-05-18

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1517/17425247.2011.574122PMID 21591841
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemotherapy against human African trypanosomiasis: Is there a road to success?

  2010cited by this paper
• Human African trypanosomiasis

  2010influential reference
• Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness

  2010cited by this paper
• NECT Is Next: Implementing the New Drug Combination Therapy for Trypanosoma brucei gambiense Sleeping Sickness

  2010cited by this paper
• Development of a nanoparticulate formulation of diminazene to treat African trypanosomiasis

  2010cited by this paper
• Positively-Charged, Porous, Polysaccharide Nanoparticles Loaded with Anionic Molecules Behave as ‘Stealth’ Cationic Nanocarriers

  2009cited by this paper
• Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier.

  2009cited by this paper
• Chapter 1 - Drug delivery to the brain using colloidal carriers.

  2009cited by this paper
• Particles induce apical plasma membrane enlargement in epithelial lung cell line depending on particle surface area dose

  2009cited by this paper
• Interaction between nitroheterocyclic compounds with beta-cyclodextrins: phase solubility and HPLC studies.

  2008cited by this paper
• Enhancement of hydrophilic drug loading and release characteristics through micellization with new carboxymethyldextran-PEG block copolymers of tunable charge density.

  2008cited by this paper
• Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles

  2008cited by this paper
• In vivo distribution of arsonoliposomes: effect of vesicle lipid composition.

  2008cited by this paper
• Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice.

  2008cited by this paper
• Human African trypanosomiasis: pharmacological re‐engagement with a neglected disease

  2007influential reference
• Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro.

  2007cited by this paper
• Fabrication, characterization and drug loading of pH-dependent multi-morpho- logical nanoparticles based on cellulose

  2007cited by this paper
• Trypanocidal activity of arsonoliposomes: effect of vesicle lipid composition.

  2007cited by this paper
• Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles.

  2007cited by this paper
• EFFICACY OF DIPALMITOYLPHOSPHATIDYLCHOLINE LIPOSOME AGAINST AFRICAN TRYPANOSOMES

  2006cited by this paper
• Complexes of poly(ethylene oxide)-block-poly(L-glutamate) and diminazene.

  2006cited by this paper
• Incorporation of PEG-lipids in arsonoliposomes results in formation of highly stable arsenic-containing vesicles.

  2006cited by this paper
• Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.

  2006cited by this paper
• Ktenate nanoparticles (bdellosomes): a novel strategy for delivering drugs to parasites or tumours

  2005cited by this paper
• The chemotherapy of chagas' disease: an overview.

  2005cited by this paper
• Synthesis of a novel PEG-block-poly(aspartic acid-stat-phenylalanine) copolymer shows potential for formation of a micellar drug carrier.

  2005cited by this paper
• Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.

  2005cited by this paper
• Arsonoliposomes: Effect of Lipid Composition on Their Stability and Morphology

  2005cited by this paper
• The Trypanocide Diminazene Aceturate Is Accumulated Predominantly through the TbAT1 Purine Transporter: Additional Insights on Diamidine Resistance in African Trypanosomes

  2004cited by this paper
• Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption.

  2004cited by this paper
• Trypanocidal drug resistance in eastern province of Zambia.

  2004cited by this paper
• Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.

  2003influential reference
• Growth suppression of a tumorigenic rat liver cell line by the anticancer agent, ET-18-O-CH3, is mediated by inhibition of cytokinesis

  2003cited by this paper
• In‐vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in‐vivo distribution in BALB/c mice

  2003cited by this paper
• Antiprotozoal activities of phospholipid analogues.

  2003influential reference
• Non-small and small cell lung carcinoma cell lines exhibit cell type-specific sensitivity to edelfosine-induced cell death and different cell line-specific responses to edelfosine treatment.

  2003cited by this paper
• PEGylated nanoparticles for biological and pharmaceutical applications.

  2003cited by this paper
• Pentamidine uptake and resistance in pathogenic protozoa: past, present and future.

  2003cited by this paper
• Slow-release melarsoprol microparticles.

  2002cited by this paper
• Determination of diminazene aceturate in pharmaceutical formulations by HPLC and identification of related substances by LC/MS.

  2002cited by this paper
• Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier

  2002cited by this paper
• Design and Antileishmanial Activity of Amphotericin B-Loaded Stable Ionic Amphiphile Biovector Formulations

  2002cited by this paper
• Chemotherapy of human African trypanosomiasis.

  2002cited by this paper
• Lipid-Drug-Conjugate (LDC) Nanoparticles as Novel Carrier System for the Hydrophilic Antitrypanosomal Drug Diminazenediaceturate

  2002cited by this paper
• Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis

  2001cited by this paper
• Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.

  2001influential reference
• Biodegradable polymeric nanoparticles as drug delivery devices.

  2001cited by this paper
• Drug-polyionic block copolymer interactions for micelle formation: physicochemical characterisation.

  2001cited by this paper
• The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles.

  2001influential reference
• Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania.

  2000influential reference
• Treatment of human African trypanosomiasis.

  2000cited by this paper
• Problems for the chemotherapy of human African trypanosomiasis

  2000influential reference
• Physico-chemical properties of the trypanocidal drug melarsoprol.

  2000cited by this paper
• 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption.

  2000cited by this paper
• DNA multimode interaction with berenil and pentamidine; double helix stiffening, unbending and bending.

  1999cited by this paper
• Extension of the prophylactic effect of isometamidium against trypanosome infections in cattle using a biodegradable copolymer.

  1999cited by this paper
• Biodegradable polyesters for controlled release of trypanocidal drugs: in vitro and in vivo studies.

  1998cited by this paper
• Preparation and characterization of biodegradable nanospheres composed of methoxy poly(ethylene glycol) and DL-lactide block copolymer as novel drug carriers.

  1998cited by this paper
• In vitro release of trypanocidal drugs from biodegradable implants based on poly(ε-caprolactone) and poly(d,l-lactide)

  1998cited by this paper
• In vitro release of trypanocidal drugs from biodegradable implants based on poly(epsilon-caprolactone) and poly(D,L-lactide).

  1998cited by this paper
• Preparation and characterization of nanoparticles containing an antihypertensive agent.

  1998cited by this paper
• Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice.

  1998cited by this paper
• Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model.

  1997cited by this paper
• Preparation and in vitro evaluation of biodegradable poly(ϵ-caprolactone-co-d,l lactide)(X-Y) devices containing trypanocidal drugs

  1997cited by this paper
• Activity of pentamidine-loaded poly (D,L-lactide) nanoparticles against Leishmania infantum in a murine model.

  1997cited by this paper
• Ultrastructural changes in parasites induced by nanoparticle-bound pentamidine in a Leishmania major/mouse model.

  1997cited by this paper
• Prophylactic effects of isometamidium- and ethidium-sustained release devices against Trypanosoma congolense in cattle.

  1997cited by this paper
• Comparative evaluation of the prophylactic effect of slow release devices containing homidium bromide and isometamidium on Trypanosoma congolense in rabbits.

  1996cited by this paper
• Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues.

  1996influential reference
• Carbonic Anhydrase Interaction With Lipothioars Enites: A Novel Class of Isozymes I and II Inhibitors

  1996cited by this paper
• Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice.

  1996cited by this paper
• Trypanocidal value of liposomal diminazene in experimental Trypanosoma brucei evansi infection in mice.

  1996cited by this paper
• Controlled drug delivery with nanoparticles : current possibilities and future trends

  1995cited by this paper
• Uptake of Diamidine Drugs by the P2 Nucleoside Transporter in Melarsen-sensitive and -resistant Trypanosoma brucei brucei(*)

  1995cited by this paper
• Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis.

  1995cited by this paper
• Action of pentamidine-bound nanoparticles against Leishmania on an in vivo model.

  1994cited by this paper
• The treatment of human African trypanosomiasis.

  1994cited by this paper
• Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy.

  1994influential reference
• Derivation and characterization of a quinapyramine-resistant clone of Trypanosoma congolense

  1993cited by this paper
• Evaluation of the efficacy of a slow release device containing homidium bromide in rabbits infected with Trypanosoma congolense.

  1993cited by this paper
• The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action.

  1993cited by this paper
• Pharmacology of existing drugs for animal trypanosomiasis.

  1993cited by this paper
• Chemotherapy of Trypanosoma brucei infection of the central nervous system: the use of a rapid chemotherapeutic regimen and the development of post-treatment encephalopathies.

  1993cited by this paper
• Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats.

  1992cited by this paper
• Isolation of drug-resistant strains ofTrypanosoma congolense from the Lower Shabelle Region of southern Somalia

  1992cited by this paper
• Cymelarsan in the treatment of buffaloes naturally infected with Trypanosoma evansi in south China.

  1991cited by this paper
• 1,2-DIHYDROXYPROPYL-3-ARSONIC ACID: A KEY INTERMEDIATE FOR ARSONOLIPIDS

  1991cited by this paper
• Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

  1990cited by this paper
• Chemoprophylaxis of trypanosomiasis, due to Trypanosoma (Nannomonas) congolense, in rabbits using a slow release device containing homidium bromide.

  1989cited by this paper
• Malic enzyme type VII isoenzyme as an indicator of suramin resistance in Trypanosoma evansi.

  1989cited by this paper
• In vitro lysis of the bloodstream forms of Trypanosoma brucei gambiense by stearylamine-bearing liposomes

  1988cited by this paper
• Trypanocidal activity of the stearylamine-bearing liposome in vitro.

  1987cited by this paper
• Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B

  1987cited by this paper
• Fate and behavior of liposomes in vivo: a review of controlling factors.

  1987cited by this paper
• Liposomes as drug carriers in leishmaniasis and malaria.

  1986cited by this paper
• Inhibition of diamine oxidase and S-adenosylmethionine decarboxylase by diminacene aceturate (berenil).

  1986cited by this paper
• Irreversible inhibition of putrescine-stimulated S-adenosyl-L-methionine decarboxylase by berenil and pentamidine.

  1985cited by this paper
• Preparation and in vitro degradation properties of polylactide microcapsules.

  1985cited by this paper
• Topological analysis of antigenic determinants on a variant surface glycoprotein of Trypanosoma brucei.

  1984cited by this paper
• Further studies on the cell surface charge of Trypanosoma cruzi.

  1984cited by this paper

• Docking simulations and multi-parameter ADMET profiling to decode quinapyramine sulfate’s strength and weakness

  2025cites this paper
• Drug resistance in animal trypanosomiases: Epidemiology, mechanisms and control strategies

  2024cites this paper
• Preclinical evaluation of quinapyramine sulphate-loaded lipidic nanocarriers for trypanocidal effect against Trypanosoma evansi

  2023cites this paper
• Difluoromethylornithine (DFMO) and AMXT 1501 inhibit capsule biosynthesis in pneumococci

  2022cites this paper
• African trypanosome infection patterns in cattle in a farm setting in Southern Ghana.

  2022cites this paper
• Evaluasi Pemberian Obat Diminazene Aceturate Secara In Vivo Pada Mencit (Mus musculus) yang Diinfeksi Isolat Trypanosoma evansi

  2021cites this paper
• Tribute to David John Fluck: Pioneer in developing unique liposome-anti-trypanosomal drug systems

  2021cites this paper
• Nano Based Approach for the Treatment of Neglected Tropical Diseases

  2021cites this paper
• Single-Domain Antibodies: Biology, Engineering and Emerging Applications

  2020cites this paper
• Sleeping sickness

  2020cites this paper
• Nanotechnological interventions for treatment of trypanosomiasis in humans and animals

  2020cites this paper
• Nanoparticle-mediated drug delivery: blood-brain barrier as the main obstacle to treat infectious diseases in CNS.

  2019cites this paper
• Modelling appropriate use of trypanocides to restrict wide-spread multi-drug resistance during chemotherapy of animal African trypanosomiasis

  2018cites this paper
• African Trypanosomes Undermine Humoral Responses and Vaccine Development: Link with Inflammatory Responses?

  2017cites this paper
• Nanobodies As Tools to Understand, Diagnose, and Treat African Trypanosomiasis

  2017cites this paper
• IV Symposium of Tropical Health/COST Action CM 1307 (WG3 and WG4) Joint Meeting Priorities in Tropical Health and parasite-borne disease: new drugs with new targets, and how to deliver them

  2017cites this paper
• The animal trypanosomiases and their chemotherapy: a review

  2016cites this paper
• Immune Evasion Strategies of Trypanosoma brucei within the Mammalian Host: Progression to Pathogenicity

  2016cites this paper
• Evaluation of antimicrobial activity of silver nanoparticles synthesized by green rout

  2015cites this paper
• Evaluation of metal nanoparticles for drug delivery systems

  2014cites this paper
• Re-Evaluate Interrelationship Dose-Response of Diminazene Aceturate Against to Infected Mice of Trypanosoma Evansi Bangkalan Isolates

  2013cites this paper
• The In Vitro Efficacy of Antimicrobial Agents Against the Pathogenic Free‐Living Amoeba Balamuthia mandrillaris

  2013cites this paper
• Nanopharmaceuticals and Nanocosmeceuticals

  2013cites this paper
• Innovative lead compounds and formulation strategies as newer kinetoplastid therapies.

  2012cites this paper
• Drug screening of Bisnaphthalimidopropyl derivatives on Trypanosoma brucei

  2012influential citation
• Enzymatic and crystallisation studies of CATL-like trypanosomal cysteine peptidases.

  2011influential citation